The World Health Organization published the preferred product characteristics for a Group A Streptococcus (Strep A) vaccine in 2018. Based on these parameters for the age of vaccination, vaccine efficacy, duration of protection from vaccine-derived immunity, and vaccination coverage, we developed a static cohort model to estimate the projected health impact of Strep A vaccination at the global, regional, and national levels and by country-income category. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• Jun 2023

Children with comorbidities are at greater risk of severe influenza outcomes compared with healthy children. In Australia, influenza vaccination was funded for those with comorbidities from 2010 and all children aged <5 years from 2018. Influenza vaccine coverage remains inadequate in children with and without comorbidities. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• March 2022

Children globally have been profoundly impacted by the coronavirus disease 2019 (COVID-19) pandemic. This review explores the direct and indirect public health impacts of COVID-19 on children. We discuss in detail the transmission dynamics, vaccination strategies and, importantly, the ‘shadow pandemic’, encompassing underappreciated indirect impacts of the pandemic on children. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• January 2022

The suboptimal sensitivity and specificity of available diagnostic methods for scabies hampers clinical management, trials of new therapies and epidemiologic studies. Additionally, parasitologic diagnosis by microscopic examination of skin scrapings requires sample collection with a sharp scalpel blade, causing discomfort to patients and difficulty in children. Polymerase chain reaction (PCR)-based diagnostic assays, combined with non-invasive sampling methods, represent an attractive approach. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• February 2021

The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• October 2020

We write this perspective to raise awareness of antimicrobial resistance as an issue in Indigenous primary health care ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• July 2019

Scabies and impetigo are common in Timor-Leste, with very high prevalence of scabies in the rural district of Ermera ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2018
• May 2018

Asha Jonathan Marianne Bowen Carapetis AM Mullane AC JR MM BA MBBS DCH FRACP PhD GAICD OAM AM MBBS FRACP FAFPHM PhD FAHMS BSc (OT) Head, Healthy Skin ...

• Telethon Kids Institute
• Projects

Christopher Hannah Blyth Moore CC HC MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD Director, Wesfarmers Centre of Vaccines and ...

• Telethon Kids Institute
• Projects

Asha Jonathan Bowen Carapetis AM AC JR BA MBBS DCH FRACP PhD GAICD OAM AM MBBS FRACP FAFPHM PhD FAHMS Head, Healthy Skin and ARF Prevention Executive ...

• Telethon Kids Institute
• Projects
• Penicillin Program